These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32739496)

  • 21. Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov.
    Bothwell LE; Avorn J; Khan NF; Kesselheim AS
    BMJ Open; 2018 Feb; 8(2):e018320. PubMed ID: 29440155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adaptive designs in clinical trials: why use them, and how to run and report them.
    Pallmann P; Bedding AW; Choodari-Oskooei B; Dimairo M; Flight L; Hampson LV; Holmes J; Mander AP; Odondi L; Sydes MR; Villar SS; Wason JMS; Weir CJ; Wheeler GM; Yap C; Jaki T
    BMC Med; 2018 Feb; 16(1):29. PubMed ID: 29490655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptive clinical trial designs in oncology.
    Zang Y; Lee JJ
    Chin Clin Oncol; 2014 Dec; 3(4):49. PubMed ID: 25841530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive clinical trial designs in oncology.
    Zang Y; Lee JJ
    Chin Clin Oncol; 2014 Dec; 3(4):. PubMed ID: 25811018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sample size re-estimation in adaptive enrichment design.
    Lin R; Yang Z; Yuan Y; Yin G
    Contemp Clin Trials; 2021 Jan; 100():106216. PubMed ID: 33246098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The extension of 2-in-1 adaptive phase 2/3 designs and its application in oncology clinical trials.
    Fan L; Zhao J; Li W
    Contemp Clin Trials; 2020 Nov; 98():106148. PubMed ID: 32949732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adaptive design clinical trials and trial logistics models in CNS drug development.
    Wang SJ; Hung HM; O'Neill R
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):159-66. PubMed ID: 20933373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Practical Perspective: Application of the Generalized Approach for Adaptive Design.
    Wang J; Li J; Shu Y; Su X
    Ther Innov Regul Sci; 2020 Jan; 54(1):167-170. PubMed ID: 32008229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines.
    Mistry P; Dunn JA; Marshall A
    BMC Med Res Methodol; 2017 Jul; 17(1):108. PubMed ID: 28720094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adaptive clinical trials: progress and challenges.
    Coffey CS; Kairalla JA
    Drugs R D; 2008; 9(4):229-42. PubMed ID: 18588354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Systematic Review of Adaptive Seamless Clinical Trials for Late-Phase Oncology Development.
    Broglio K; Cooner F; Wu Y; Xiao M; Xue XQ; Lowen M; Ikhapoh I; He P
    Ther Innov Regul Sci; 2024 Jun; ():. PubMed ID: 38861131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?
    Parke T; Marchenko O; Anisimov V; Ivanova A; Jennison C; Perevozskaya I; Song G
    J Biopharm Stat; 2017; 27(3):457-476. PubMed ID: 28281911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RESTART trial design: two-stage seamless transition design with operational considerations.
    Yi M; Zhuo B; Cooner F
    J Biopharm Stat; 2023 Nov; 33(6):820-829. PubMed ID: 36653753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.
    Bauer P; Bretz F; Dragalin V; König F; Wassmer G
    Stat Med; 2016 Feb; 35(3):325-47. PubMed ID: 25778935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel dose-finding designs and considerations on practical implementations in oncology clinical trials.
    Huang B; Bycott P; Talukder E
    J Biopharm Stat; 2017; 27(1):44-55. PubMed ID: 26882496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adaptive designs for single-arm phase II trials in oncology.
    Englert S; Kieser M
    Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using surrogate information to improve confirmatory platform trial with sample size re-estimation.
    Zhong C; Li Q; Wu L; Lin J
    J Biopharm Stat; 2022 Jul; 32(4):547-566. PubMed ID: 35714331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challenges.
    Chen YH; Gesser R; Luxembourg A
    Clin Trials; 2015 Feb; 12(1):84-90. PubMed ID: 25278227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.